Brief: Celldex Announces First Patient Dosed In Phase 2 Study Of Barzolvolimab In Eosinophilic Esophagitis
06/07/2023 14:38
July 6 (Reuters) - Celldex Therapeutics Inc CLDX.O :
* CELLDEX ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 STUDY OF
BARZOLVOLIMAB IN EOSINOPHILIC ESOPHAGITIS
Source text for Eikon: ID:nGNX1GtkWs
Further company coverage: CLDX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials